Rising energy costs and inflation worries are putting pressure on many sectors, yet healthcare spending in the UK tends to be more resilient when wallets tighten. That gives high quality British healthcare stocks with solid balance sheets and clear business models a particular appeal. This article walks through three of the strongest candidates from our healthcare shortlist to help you focus your research on robust, long term themes.
The three stocks below are a useful starting sample, yet the full healthcare screen also flags 2 more businesses with equally compelling stories that are not covered here.
If you want to identify your own high conviction ideas across providers, pharma, biotech and equipment, head straight to the Best Healthcare Stocks screener to filter the field and analyze the standouts.
NIOX Group (AIM:NIOX)
Overview:NIOX Group develops and sells its NIOX VERO point of care FeNO devices and consumables used to diagnose and monitor asthma and COPD.
Operations:The business generates its £47.5 million revenue from the NIOX branded FeNO respiratory diagnostics platform and related disposables.
Market Cap:£286.2 million
NIOX Group provides focused exposure to asthma and COPD diagnostics, with its NIOX VERO device and mouthpieces positioned in healthcare equipment and technology. Profitability in the latest half year remained around £24 million of revenue and £5.9 million of net income. The analysis for this screener centres on how one less obvious factor may influence future pricing power in this niche.
To see how that pricing power theme is built into the numbers, review the analysis report for NIOX Group and judge whether NIOX Group's niche is being fully credited yet.
HUTCHMED (China) (AIM:HCM)
Overview:HUTCHMED (China) develops targeted cancer medicines and immunotherapies, centring on approved and late stage oncology drugs that anchor its healthcare focus.
Operations:The group generated about $245 million from Other Ventures and $305 million from Oncology and Immunology, mostly in China, with smaller U.S. and international contributions.
Market Cap:£1.88 billion
HUTCHMED (China) connects directly to the Best Healthcare Stocks theme through its oncology drugs. Approved therapies and a substantial late stage pipeline provide exposure to cancer treatments that are linked to real world demand and large addressable patient pools, rather than early stage science alone.
"Expansion of approved indications and upcoming NDA submissions for key oncology products (savolitinib and fruquintinib) are set to drive higher revenue growth, leveraging strong demand from an aging population and increased chronic disease prevalence in China and globally."
The key swing factor is how one emerging pressure on future profitability resolves, which could significantly influence how investors view this story.
How that profitability pressure plays out is exactly what the full narrative for HUTCHMED (China) unpacks, including how HUTCHMED (China) could still accelerate if sentiment is currently masking the core story.
Integrated Diagnostics Holdings (LSE:IDHC)
Overview:Integrated Diagnostics Holdings runs medical labs and imaging centres across MENA, providing thousands of routine and specialised tests directly linked to everyday healthcare demand.
Operations:Integrated Diagnostics Holdings generated EGP 2,941 million from walk-in patients and EGP 6,229 million from contract customers, mainly in Egypt and Jordan.
Market Cap:$291 million
Integrated Diagnostics Holdings matters for the Best Healthcare Stocks theme because it offers essential diagnostic services that patients and hospitals rely on every single day, and its expanding footprint across key MENA markets increases the reach of that testing network.
"The decision to acquire the remaining 49% stake in the Saudi Arabian venture gives IDH full control over the entity, enabling more flexible execution of its growth strategy in a high-potential market, supporting revenue and possibly net margins as operations scale."
One key question is what happens if a shift in how these diagnostic centres are funded affects the durability of that margin profile.
If that funding shift is the real hinge, the full narrative for Integrated Diagnostics Holdings shows where IDH's margins could decouple from expectations and why sentiment may be missing the upside.
Seeking Alternatives Beyond Healthcare?
Fresh themes move fast. Some sectors are building breakout momentum while others get quietly dropped by the crowd. Scan these curated lists before the window closes and get in early.
-
Spot resilient cash generators early by running through a curated list of solid balance sheet and fundamentals (9 results) that can keep you focused on businesses built to handle shocks.
-
Explore AI-driven efficiency by zeroing in on 92 robotics and automation stocks that could benefit as automation spending gains traction.
-
Review opportunities around power infrastructure upgrades by checking 41 power grid technology and infrastructure stocks as the grid modernisation story develops.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
